Sudeep Pharma Q3FY26 Investor Presentation Released; Earnings Call on Feb 9
Sudeep Pharma's Q3FY26 investor presentation shows 52% YoY revenue growth to ₹179.2 crore. EBITDA and PAT grew 60% and 66% YoY. The company is building a battery chemicals plant in Dahej, with commissioning expected by Q4 FY26.
The announcement includes strong financial performance for the quarter and significant strategic initiatives like capacity expansion and entry into the battery chemicals market, which are likely to have a substantial impact on the company's future growth and market position.
The company reported strong year-over-year growth in revenue, EBITDA, and PAT, along with strategic expansion into new high-growth areas like battery materials, indicating positive business momentum.
Sudeep Pharma Limited has released its investor presentation for the third quarter and nine months ended December 31, 2025 (Q3FY26). The company has scheduled an earnings call on Monday, February 9, 2026, at 11:00 a.m. to discuss its operational and financial performance.
Key highlights from the presentation include a significant YoY revenue growth of 52% for Q3FY26, reaching ₹179.2 crore, and EBITDA and PAT growth of 60% and 66% YoY, respectively. The company is expanding into battery chemicals with a new plant at Dahej, Gujarat, targeting a Phase I capacity of 25,000 MT per annum. The greenfield manufacturing facility at Nandesari is progressing as planned and is expected to be commissioned by Q4 FY26. The acquisition of NSS is integrating well, strengthening advanced formulation capabilities and global customer reach. The MD's message emphasizes strong demand across business segments and confidence in creating long-term value.
What to do with a filing like this
Sudeep Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sudeep Pharma Limited. Read the original for the full detail.